Compare State Street Real Estate Select Sector SPDR ETF (XLRE) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street Real Estate Select Sector SPDR ETF vs Zoetis Inc — how do they compare? State Street Real Estate Select Sector SPDR ETF trades at $43.42, while Zoetis Inc trades at $73.65 (market cap $30.40B). The key difference: Zoetis Inc pays a 2.88% dividend while State Street Real Estate Select Sector SPDR ETF pays none, and State Street Real Estate Select Sector SPDR ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| XLRE | ZTS | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $46.01 | $150.61 |
52-Week Low | $40.01 | $71.91 |
Market Cap | — | $30.40B |
Enterprise Value | — | $37.96B |
Dividend Yield | — | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XLRE trades at $43.9, down 0.05% with a bearish technical signal from moving averages. The ETF shows neutral oscillator readings, with RSI near oversold levels. Recent news highlights real estate's resilience amid inflation, though some analysts warn of underperformance versus AI-focused alternatives. Dividend safety remains a focus, with a future dividend scheduled for June 2026.
Outlook is mixed; real estate offers diversification and income potential, but high interest rates and sector rotation pose risks. Investors should weigh XLRE's low expense ratio and U.S. focus against macroeconomic headwinds. Sentiment is cautious, with technical weakness suggesting near-term pressure.
Zoetis (ZTS) trades at $73.60, down 2.92% amid bearish technical signals and mixed earnings. The stock faces pressure from weakening U.S. companion animal sales and competitive headwinds, though profitability remains strong with 71.67% gross margins and 27.69% net income margin. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a guidance cut. Analyst consensus is divided with 45% Buy ratings and a $93.40 price target, suggesting 27% upside from current levels.
The outlook balances valuation appeal (P/E of 12) against near-term operational challenges. Investment opportunity lies in market dominance and robust cash flow generation, while risks include sustained pet health demand softness and competitive pricing pressure. The stock trades near support at $73, with institutional sentiment mixed amid recent portfolio adjustments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About State Street Real Estate Select Sector SPDR ETF
XLRE tracks the Real Estate Select Sector Index, providing exposure to S&P 500 real estate companies. It focuses on equity REITs across residential, industrial, and healthcare sub-sectors, with top holdings like Welltower, Prologis, and American Tower.
Read more on XLRE →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
